Dr. Khemees completed his SUO fellowship in urologic oncology at UW in 2020 and will be joining the Central Ohio Urology Group in Columbus, OH. While at UW, Dr. Khemees published three articles as primary author and contributed to three others. He presented papers at the Society of Urologic Oncology annual meetings, the 2018 Society for Basic Urologic Research annual meeting, as well as at the American Urological Association. He won a best poster award at the SUO for his work looking at urine markers.
Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: A large observational study.
The Evolving Treatment of Metastatic Hormone Sensitive Prostate Cancer.
Shivashankar Damodaran, MD
Previous position: Assistant Professor of Urology and General Surgery in Sri Satya Sai Medical College and Research Institute
Dr. Damodaran completed his SUOfellowship in urologic oncology at UW in 2018 and is currently a urology resident at the University of Toledo. During his time at UW, he published nine manuscripts as well as writing several book chapters. He additionally has seven other manuscripts that are in review. He presented papers at both the Society of Urologic Oncology meetings, Wisconsin Urologic, as well as at the American Urological Association.
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
Damodaran S, Kyriakopoulos CE, Jarrard DF.
Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences.
Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, Jarrard DF, Downs TM.
Chondroma of the Bladder: A Case Report and Review of the Literature.
Tazeh NN, Scott K, Damodaran S, Huang W, Downs TM.
Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
Blute ML Jr, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM.
Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S, Damaschke N, Gawdzik J, Yang B, Shi C, Allen GO, Huang W, Denu J, Jarrard D.
Clinical and pathologic factors predicting reclassification in active surveillance cohorts.
Sierra PS, Damodaran S, Jarrard D.
Michael Blute, MD
University of Florida at Gainsville
Dr. Blute completed his SUO fellowship requirements at Wisconsin in 2016 and was appointed assistant professor in the Department of Urology at the University of Florida. During his time at Wisconsin he worked on basic science and clinical research projects, and he was funded by a T32 training grant. As a fellow, Dr. Blute’s work resulted in 10 first author (16 total) peer reviewed manuscripts. His manuscripts were published in high-impact journals including Journal of Clinical Oncology, Journal of Urology, and European Urology.
During the 2015 AUA, Dr. Blute presented seven abstracts at the AUA national meeting in New Orleans, LA, a new record for Wisconsin fellows. One of his presentations won a coveted best poster award for “Renin-angiotensin Inhibitors in Bladder Cancer Progression,” and a second presentation was featured in the take home points.
Clinically, Dr. Blute was exposed to broad training in minimally invasive and open surgery for complex urologic cancers including post-chemotherapy retroperitoneal lymph node dissection, cystectomy and cytoreductive nephrectomy.
Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis
Blute ML Jr, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM,
Grimes M, Shi F, Mann MA, Abel EJ
A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer
Blute ML Jr, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF
A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery
Grimes MD, Blute ML Jr, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard
DF, Best SL, Richards KA, Nakada SY, Abel EJ
Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer
Blute ML Jr, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards
K, Nakada SY, Abel EJ
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection ofBladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer
Blute ML Jr, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM
Addressing the need forrepeat prostate biopsy: new technology and approaches
Blute ML Jr, Abel EJ, Downs TM, Kelcz F, Jarrard DF
Frequent disruption of chromodomain helicase DNA-binding protein 8 (CHD8) and functionallyassociated chromatin regulators in prostate cancer
Damaschke NA, Yang B, Blute ML Jr, Lin CP, Huang W, Jarrard DF
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications
Blute ML Jr, Damaschke NA, Jarrard DF
Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer
Jarrard DF, Blute ML Jr, Ritter MA
Pablo Sierra, MD
Urólogo Fundación Valle del Lili in Cali, Columbia
Dr. Sierra recently completed a research fellowship in urologic oncology and has joined the faculty as a new Professor at the Urólogo Fundación Valle del Lili in Cali Columbia. He completed his residency training at the Universidad CES, Medellin Columbia. His recently completed manuscripts involve improving risk prediction for patients considering active surveillance.
Bilateral Prostate Cancer On Prostate Biopsy in Patients Considering Active Surveillance Predicts Subsequent Upgrading: Detection Not Progression
Sierra P, Wang JH, Richards KA, Abel J, Downs T, Shi F, and Jarrard DF
Clinical and Pathologic Factors Predicting Reclassification in Active Surveillance Cohorts
Sierra P, Wang JH, Richards KA, Abel J, Downs T, and Jarrard DF
Matthew Truong, MD
Dr. Matthew Troung completed a research fellowship in urologic oncology at UW and is currently a urology resident at the University of Rochester. During his time at UW, he was funded through an AUA Herbert Brendler award and a Shapiro Research Scholarship. He published 10 peer reviewed manuscripts, five as first author including a seminal paper developing a nomogram for predicting cancer upgrading (Cancer 2014) and developing new epigenetic prostate cancer biomarkers (J Urol 2013).
Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
Truong M, Yang B, Wagner J, Kobayashi Y, Rajamanickam V, Brooks J, Jarrard DF, Br J Cancer
CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer
Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W, Jarrard D
Toward the detection of prostate cancer in urine: a critical analysis
Truong M, Yang B, Jarrard DF
Analysis of promoter non-CG methylation in prostate cancer
Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF
Analysis of urological procedures in men who died from prostate cancer using a population-based approach
Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, Jarrard DF
HP1γ expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy
Slezak J, Truong M, Huang W, Jarrard D
Using the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy-Negative Patients
Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer
Truong M, Slezak JA, Lin CP, Iremashvili V, Sado M, Razmaria AA, Leverson G, Soloway MS, Eggener SE, Abel EJ, Downs TM, Jarrard DF
Overexpression of the Novel Senescence Marker β-Galactosidase (GLB1) in Prostate Cancer Predicts Reduced PSA Recurrence
Wagner J, Damaschke N, Truong M, Yang B, Guenther C, Huang W, Jarrard DF
2015 Apr 15;10(4):e0124366
PubMed PMID: 25876105; PubMed Central PMCID: PMC4398352
A Biopsy-Integrated Algorithm for Determining Gleason 6 Upgrading In Prostate Cancer Stratifies Risk of Active Surveillance Failure
Blute, Jr. ML, Shiau JM, Truong ME, Abel EJ, Downs TM, Jarrard DF